Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
Provided By PR Newswire
Last update: Nov 28, 2024
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.
Read more at prnewswire.comNASDAQ:LI (9/22/2025, 12:54:50 PM)
25.395
-0.36 (-1.38%)
NYSE:WDH (9/22/2025, 12:53:26 PM)
1.965
+0.03 (+1.29%)
Find more stocks in the Stock Screener
